Production of vaccines

Details Production of vaccines Production of vaccines

2011-06-21

2011-06-21

Mosher, Mary E (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S204100, C424S210100, C435S069100, C530S350000

Reexamination Certificate

active

07964198

ABSTRACT:
Means and methods for producing mammalian viruses, the method comprising infecting a culture of immortalized human cells with a virus, incubating the culture infected with virus to propagate the virus under conditions that permit growth of the virus, and to form a virus-containing medium, and removing the virus-containing medium. The viruses can be harvested and be used for the production of vaccines. Advantages include that human cells of the present invention can be cultured under defined serum-free conditions and the cells show improved capability for propagating virus. Methods are provided for producing, in cultured human cells, influenza virus and vaccines derived thereof. This method eliminates the necessity of using whole chicken embryos for the production of Influenza vaccines. The method also provides for the continuous or batch-wise removal of culture media. As such, the present invention allows the large-scale continuous production of viruses to a high titer.

REFERENCES:
patent: 4703008 (1987-10-01), Lin
patent: 4835260 (1989-05-01), Shoemaker
patent: 5047335 (1991-09-01), Paulson et al.
patent: 5441868 (1995-08-01), Lin
patent: 5457089 (1995-10-01), Fibi et al.
patent: 5494790 (1996-02-01), Sasaki et al.
patent: 5518913 (1996-05-01), Massie et al.
patent: 5631158 (1997-05-01), Dorai et al.
patent: 5714587 (1998-02-01), Laine
patent: 5767078 (1998-06-01), Johnson et al.
patent: 5773569 (1998-06-01), Wrighton et al.
patent: 5789247 (1998-08-01), Ballay et al.
patent: 5830851 (1998-11-01), Wrighton et al.
patent: 5835382 (1998-11-01), Wilson et al.
patent: 5856298 (1999-01-01), Strickland
patent: 5994128 (1999-11-01), Fallaux et al.
patent: 6033908 (2000-03-01), Bout et al.
patent: 6395519 (2002-05-01), Fallaux et al.
patent: 6413746 (2002-07-01), Field
patent: 6475753 (2002-11-01), Ruben et al.
patent: 6492169 (2002-12-01), Vogels et al.
patent: 6506598 (2003-01-01), Andersen et al.
patent: 6558948 (2003-05-01), Kochanek et al.
patent: 6653101 (2003-11-01), Cockett et al.
patent: 6855544 (2005-02-01), Hateboer et al.
patent: 6878549 (2005-04-01), Vogels et al.
patent: 7125706 (2006-10-01), Zhang et al.
patent: 7192759 (2007-03-01), Pau et al.
patent: 7297680 (2007-11-01), Opstelten et al.
patent: 7470523 (2008-12-01), Bout et al.
patent: 7491532 (2009-02-01), Bout et al.
patent: 7504248 (2009-03-01), Marzio et al.
patent: 2002/0116723 (2002-08-01), Grigliatti et al.
patent: 2003/0087437 (2003-05-01), Asada et al.
patent: 2003/0092160 (2003-05-01), Bout et al.
patent: 2005/0164386 (2005-07-01), Uytdehaag et al.
patent: 2005/0170398 (2005-08-01), Van Berkel et al.
patent: 2007/0231860 (2007-10-01), UytdeHaag et al.
patent: 2007/0298464 (2007-12-01), Opstelten et al.
patent: 2008/0050403 (2008-02-01), Marzio et al.
patent: 2008/0131461 (2008-06-01), Pau et al.
patent: 2009/0170164 (2009-07-01), Hateboer et al.
patent: 2009/0285879 (2009-11-01), Pau et al.
patent: 2009/0324645 (2009-12-01), Pau et al.
patent: 2010/0015176 (2010-01-01), Havenga et al.
patent: 0 411 678 (1991-02-01), None
patent: 0 185 573 (1995-06-01), None
patent: 0 833 934 (1998-04-01), None
patent: 1 108 787 (2001-06-01), None
patent: WO 93/03163 (1993-02-01), None
patent: WO 95/05465 (1995-02-01), None
patent: WO 95/29994 (1995-11-01), None
patent: WO 97/00326 (1997-01-01), None
patent: WO 98/18926 (1998-05-01), None
patent: WO 98/39411 (1998-09-01), None
patent: WO 98/44141 (1998-10-01), None
patent: WO 99/05268 (1999-02-01), None
patent: WO 99/24068 (1999-05-01), None
patent: WO 00/61164 (2000-10-01), None
patent: WO 00/63403 (2000-10-01), None
patent: WO 01/05945 (2001-01-01), None
patent: WO 01/38362 (2001-05-01), None
patent: WO0188117 (2001-11-01), None
patent: WO 02/018948 (2002-03-01), None
patent: WO 02/053580 (2002-07-01), None
patent: WO 03/038100 (2003-05-01), None
patent: WO 03/048197 (2003-06-01), None
patent: WO 03/048348 (2003-06-01), None
patent: WO 03/051927 (2003-06-01), None
patent: WO 2004/003176 (2004-01-01), None
patent: WO 2004/099396 (2004-11-01), None
Hoffmann et al., Proc Natl Acad Sci U S A. 2000 vol. 97(11):6108-13.
Schultz-Cherry J Clinical Micro 1998 vol. 36, pp. 3718-3720.
Schwarzer et al., Vaccine 2009 vol. 27, pp. 4325-4336.
Donatelli et al., J. Gen. Virol., 2001. pp. 623-630, vol. 82.
Pau et al., The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines, Vaccine, 2001, pp. 2716-2721, vol. 19, No. 17-19.
Certificate of deposit of the PER.C6 cell line (ECACC deposit under No. 96022940), Feb. 29, 1996.
GIBCO cell culture, A Guide to Serum-Free Cell Culture, www.invitrogen.com, (last visited Jun. 14, 2010).
Marketing Authorization and Scientific Discussion for Xigris date of issue of Marketing Authorisation Aug. 22, 2002.
NCBI Entrez Nucleotide accession No. X02996 J01967 J01968 J01970 J01971 J01972 J01974 J01976 J01977 J01978 J01979 K00515 V00025 V00026 V00027 V00029 dated Feb. 9, 2005.
NCBI Entrez Nucleotide accession No. NC—002018 (last visited Jun. 25, 2003).
NCBI Entrez Nucleotide accession No. U38242 (last visited Jun. 25, 2003).
Notice of Opposition to a European Patent for 1 161 548 by Serono Nov. 16, 2005.
Berg et al., Ela-responsive mammalian host-vector system for the stable high-level expression of secreted proteins, Nucleic Acids Research, 1992, pp. 5485-5486, vol. 20, No. 20.
Bout et al., “PER.C6 as production platform for human monoclonal antibodies,” Human Antibodies, Oct. 8, 2003, pp. 30, vol. 12, No. 1-2.
Jones et al., “High-Level Expression of Recombinant IgG in the Human Cell Line PER.C6,” Biotechnology Progress, Jan. 14, 2003, pp. 163-168, vol. 19.
Jones et al., “PER.C6 Cell Line for Human Antibody Production: Crucell's Technology Maintains ‘Human’ Glycoylation Patterns,” Genetic Engineering News, May 15, 2002, pp. 50, 54, vol. 80, No. 5.
PCT International Preliminary Report, PCT/EP2004/050724, dated Jan. 27, 2005.
PCT International Search Report, PCT/EP2004/050724, dated Oct. 1, 2004.
PCT International Search Report, PCT/NL02/00804, dated Sep. 26, 2003.
Pham et al., Abstract, “Large-Scale Transient Transfection of Serum-Free Suspension-Growing HEK293 EBNA1 Cells: Peptone Additives Improve Cell Growth and Transfection Efficiency,” Biotechnology and Bioengineering, Nov. 5, 2003, pp. 332-342, vol. 84, No. 3.
Trudel et al., Process Biochemistry Jan./Feb. 1983, pp. 2-4 and 9.
Kurokawa et al., Biotech. Bioeng. 1994, vol. 44, pp. 95-103.
Varki et al., Essentials of glycobiology, 1999, Cold Spring harbor Laboratory Press, Cold Spring Harbor, New York.
Yatsiv et al., Erythropoietin is Neuroprotective, Improves Functional Recovery, and Reduces Neuronal Apoptosis and Inflammation in a Rodent Model of Experimental Closed Head Injury, Faseb J., 2005, vol. 19, pp. 1701-1703.
Matsumoto et al., Characterization of a Human Glycoprotein (Erythropoietin) Produced in Cultured Tobacco Cells, Plant Mol. Biol., 1995, vol. 27, pp. 1163-1172.
Walls et al., Amplification of multicistronic plasmids in the human 293 cell line and secretion of correctly processed recombinant human protein C, Gene, 1989, pp. 139-149, vol. 81.
Xie et al., “Large-Scale Propagation of a Replication-Defective Adenovirus Vector in Stirred-Tank Bioreactor PER.C6 Cell Culture Under Sparging Conditions,” Jul. 5, 2003, Biotechnology and Bioengineering, pp. 45-52, vol. 83, No. 1.
Xie et al.. “Serum-Free Suspension Cultivation of PER.C6 Cells and Recombinant Adenovirus Production Under Different pH Conditions,” Biotechnology and Bioengineering, Dec. 5, 2002, pp. 569-579, vol. 80, No. 5.
Yan et al., Novel Asn-linked oligosaccharides terminating in GaINAcbeta(1-4)[Fucalpha(1-3)]GIcNAcbeta(1-.) are present in recombinant human Protein C expressed in human kidney 293 cells, Glycobiology, 1993, pp. 597-608, vol. 3. No. 6.
Yeager et al., Constructing immortalized human cell lines, Current Opinion Biotechnology, 1999, pp. 465-469, vol. 10.
Yeh et al., Adenoviral Vectors, pp. 25-42 of “Concepts in Gene Therapy,” 1997, Publisher: Walter de Gruyter, New

Affiliated with

Also associated with

Rating

Production of vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Production of vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Production of vaccines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2716701